SYGNIS Signs Initial Distribution Agreement with FUNAKOSHI
News Mar 05, 2015
SYGNIS AG has announced that it has signed an non-exclusive distribution agreement for SYGNIS’ TruePrime™ family with FUNAKOSHI Co. Ltd. for the Japanese market.
With this agreement, SYGNIS grants FUNAKOSHI the non-exclusive rights to promote, market and sell all existing as well as future products for DNA and RNA amplification from smallest amounts of samples down to single cells for applications such as next generation sequencing (NGS) in Japan.
SYGNIS’ TruePrime™ product family is based on SYGNIS’ revolutionary novel multiple displacement amplification (MDA) technology for the amplification of various DNA or RNA species for a multitude of applications.
As a leading solution provider, FUNAKOSHI is offering a broad portfolio of quality research reagents as well as high-tech instruments in the wide fields of molecular biology, protein research, cell biology and diagnostics to customers all over Japan.
“We are very pleased about this distribution agreement for our proprietary product portfolio with FUNAKOSHI, an important gatekeeper in Japan, the second largest life science market in the world today. With its wide customer network focused on molecular biology and diagnostics, FUNAKOSHI is best positioned to leverage the benefits of our existing as well as future products to customers in molecular biology especially in the fast growing field of NGS in Japan,” Pilar de la Huerta, CEO and CFO of SYGNIS commented.
Huerta continued, “After we successfully signed distributions agreements for North America and Europe, we today were able to sign the initial agreement for the Asian markets. We are very focused and committed to building up and expanding our distribution channel program in 2015 and only just have started with our extensive marketing activities in order to make our product widely available.”
Ancient Fish Genes May Hold Key to Spinal Cord RepairNews
A study has found that genes controlling spinal cord repair in the lamprey fish are also active in mammals, which could provide a blueprint for treatment.READ MORE
Prostate Tumor Progression Dictated by Cancer’s Gene-determined “Immune Landscape”News
The field of immunotherapy is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of patients, suggesting that as-yet unidentified variations among tumors result in distinct paths of disease progression and response to therapy.READ MORE